Jazz, Hikma Must Face Bulk Of Xyrem Antitrust Suit

By Bryan Koenig · August 28, 2024, 7:33 PM EDT

Jazz Pharmaceuticals and Hikma Pharmaceuticals appear bound for trial against most solo insurer and class action antitrust claims over alleged efforts to block generic competitors to Jazz's Xyrem narcolepsy drug, under...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

In re Xyrem (Sodium Oxybate) Antitrust Litigation

Case Number

3:20-md-02966

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

December 16, 2020

Featured Stories

Sales Drop, Debt, Competition Led Container Store To Ch. 11 No Photo Available

Yun Park

Stiffer competition and reduced customer spending on plastic bins, closet organizers and other items from The Container Store Group In... (more story)

Catching Up With New Bankruptcy Case Action No Photo Available

Yun Park

Biora Therapeutics filed for Chapter 11 with its plan to sell assets to fund ongoing clinical development. Ohio-based compostable film... (more story)

What Del. Legal Leaders Are Thinking About Heading Into '25 No Photo Available

Rose Krebs

Figuring out how to best use generative artificial intelligence tools in the practice of law, attracting and retaining talent in a com... (more story)